Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Open Angle Glaucoma: Treatment01:27

Open Angle Glaucoma: Treatment

In open-angle glaucoma, the iridocorneal angle remains open, but the trabecular meshwork becomes stiff, slowing down the outflow of aqueous humor. This causes a buildup of aqueous humor in the anterior chamber, leading to a sudden increase in intraocular pressure. The treatment for open-angle glaucoma focuses on reducing the elevated intraocular pressure by either decreasing the secretion of aqueous humor or increasing its outflow.
Drugs such as carbonic anhydrase inhibitors, α2- and...
Ophthalmic Drug Delivery Systems01:23

Ophthalmic Drug Delivery Systems

Ophthalmic drug delivery faces major limitations due to poor absorption across the corneal membrane. This process is primarily driven by diffusion and is influenced by two main factors: the physicochemical properties of the drug and tear drainage. Most ophthalmic drugs, such as pilocarpine, epinephrine, atropine, and local anesthetics, are weak bases. They are typically formulated at an acidic pH to enhance chemical stability. However, this leads to high ionization, reducing their ability to...
Adrenergic Antagonists: Pharmacological Actions of β-Receptor Blockers01:27

Adrenergic Antagonists: Pharmacological Actions of β-Receptor Blockers

β-receptor blockers significantly impact the cardiovascular system by counteracting catecholamine-induced sympathetic responses. These medications decrease heart rate, contractility, and cardiac output, potentially leading to cardiac depression, life-threatening bradycardia, and death. Therapeutically, β-blockers function as mild antihypertensives and are utilized in treating angina pectoris and cardiac arrhythmias. However, nonselective β-blockers inhibit β2-receptors in bronchial smooth...
Hypersensitivity Reactions: Delayed Hypersensitivity Reactions01:29

Hypersensitivity Reactions: Delayed Hypersensitivity Reactions

Delayed-Type Hypersensitivity (DTH), or Type IV hypersensitivity, is a cell-mediated immune response. It occurs when T cells, rather than antibodies, mediate a reaction to specific antigens. It is characterized by a delayed onset (1-2 days) and involves the recruitment of macrophages to the inflammation site.The initiation of a DTH response begins with the sensitization of T cells. During this phase, which lasts at least 1-2 weeks, antigen-specific T cells are activated, clonally expanded, and...
Cholinergic Antagonists: Pharmacokinetics01:24

Cholinergic Antagonists: Pharmacokinetics

Cholinergic antagonists—such as antimuscarinics—are available in oral, topical, ocular, parenteral, and inhalational formulations. Most antimuscarinics are oral formulations,  while scopolamine is available as a topical patch, and ipratropium and tiotropium are available as inhalation aerosols or powders. Atropine, tropicamide, and cyclopentolate are topically instilled in the eye. Most antimuscarinics are lipid-soluble and readily absorbed from the gastrointestinal tract and the conjunctiva.
Desensitization and Tachyphylaxis01:20

Desensitization and Tachyphylaxis

Tachyphylaxis is described as a rapid decrease in response to a drug after repeated or continuous administration of the same drug dose. It is a phenomenon where the body becomes less responsive to a particular substance or intervention over time, requiring higher doses or stronger interventions to achieve the same effect. It results from adaptive changes in the body's receptors, signaling pathways, or physiological processes that occur in response to prolonged exposure to a stimulus.
Several...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Geroprotective effects of diet and exercise plus metformin in frail older veterans with obesity: The DEMFOS randomized trial protocol.

Contemporary clinical trials·2026
Same author

Lifestyle Intervention Therapy Modulates Global DNA Methylation and Adipogenic Gene Expression in Severely Obese Hypogonadal Men.

Metabolites·2026
Same author

Testosterone plus lifestyle therapy improves skeletal muscle glycolysis in older men with obesity and hypogonadism.

Frontiers in endocrinology·2026
Same author

Role of Systemic Factors in the Progression to Vision-Threatening Diabetic Retinopathy in a New Mexican Patient Population with Type 2 Diabetes: Glycemic Control Is Not Enough.

Journal of diabetes research·2026
Same author

Correction to: High-Fidelity Finite Element Modeling Technique to Improve Sensitivity to Bone Tissue Changes of Older Adults with Obesity undergoing Intensive Lifestyle Intervention.

Annals of biomedical engineering·2026
Same author

Perceptibility of AI-revised content in pharmacy residency letters of intent.

American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists·2025

Related Experiment Video

Updated: Jun 10, 2026

Glaucoma-inducing Procedure in an In Vivo Rat Model and Whole-mount Retina Preparation
08:30

Glaucoma-inducing Procedure in an In Vivo Rat Model and Whole-mount Retina Preparation

Published on: March 12, 2016

Brimonidine hypersensitivity when switching between 0.2% and 0.15% formulations.

Michael Sullivan-Mee1, Denise Pensyl, Brooks Alldredge

  • 1Department of Surgery/section Optometry, Albuquerque VA Medical Center, Albuquerque, New Mexico 87108, USA. michael.sullivan-mee@va.gov

Journal of Ocular Pharmacology and Therapeutics : the Official Journal of the Association for Ocular Pharmacology and Therapeutics
|July 27, 2010
PubMed
Summary

Switching to generic brimonidine 0.2% showed a 7.7% hypersensitivity rate, similar to new users. Re-initiating brimonidine-purite 0.15% in hypersensitive patients had a 20% reaction rate, suggesting it

Related Experiment Videos

Last Updated: Jun 10, 2026

Glaucoma-inducing Procedure in an In Vivo Rat Model and Whole-mount Retina Preparation
08:30

Glaucoma-inducing Procedure in an In Vivo Rat Model and Whole-mount Retina Preparation

Published on: March 12, 2016

Area of Science:

  • Ophthalmology
  • Pharmacology
  • Clinical Pharmacy

Background:

  • Brimonidine-purite 0.15% is a commonly prescribed medication for glaucoma.
  • A facility formulary change necessitated a switch to generic brimonidine 0.2% for patients previously using brimonidine-purite 0.15%.

Purpose of the Study:

  • To determine the rate of ocular hypersensitivity reactions in patients switched from brimonidine-purite 0.15% to generic brimonidine 0.2%.
  • To assess hypersensitivity rates upon re-initiation of brimonidine-purite 0.15% in patients who developed hypersensitivity to generic brimonidine 0.2%.

Main Methods:

  • Retrospective chart review was conducted to identify ocular hypersensitivity reactions.
  • Patients at the Albuquerque Veterans Administration Medical Center were included after a formulary change.
  • Data on hypersensitivity to both brimonidine formulations were collected.

Main Results:

  • Out of 313 subjects, 24 (7.7%) developed hypersensitivity to brimonidine 0.2%.
  • Of the 24 patients who developed hypersensitivity to brimonidine 0.2%, 15 were re-initiated on brimonidine-purite 0.15%.
  • Three of these 15 patients (20%) subsequently developed hypersensitivity to brimonidine-purite 0.15%.

Conclusions:

  • The hypersensitivity rate to generic brimonidine 0.2% appears comparable to rates in brimonidine-naive populations.
  • Re-initiating brimonidine-purite 0.15% may be a viable treatment option for patients experiencing hypersensitivity to brimonidine 0.2%.